PMID- 11143821
OWN - NLM
STAT- MEDLINE
DCOM- 20001228
LR  - 20181130
IS  - 0004-4849 (Print)
IS  - 0004-4849 (Linking)
VI  - 92
IP  - 4-8
DP  - 2000 Apr-Aug
TI  - Excellent response to interferon therapy in a patient with hypereosinophilic 
      syndrome and elevated serum immunoglobulin E levels.
PG  - 59-62
AB  - The hypereosinophilic syndrome (HES) is a heterogeneous disease characterized by 
      sustained eosinophilia for a period of at least six months with evidence of organ 
      involvement. Its manifestations range from a benign disorder not requiring any 
      therapy to an aggressive, malignant variety refractory to common treatments. 
      Diverse therapies have been used, including steroids, hydroxyurea, and 
      chemotherapy, with variable responses. Recently alpha-interferon therapy has been 
      shown effective in this disorder. Of the various prognostic factors, elevated 
      serum immunoglobulin E (IgE) levels is considered among the most favorable, with 
      most patients presenting with a "benign" disorder, not requiring therapy. We 
      describe a patient presenting with an aggressive variant of HES despite having 
      elevated IgE levels. The patient had a dramatic and lasting response to 
      alpha-interferon.
FAU - Acaba, L
AU  - Acaba L
AD  - Hematology-Medical Oncology Section, Department of Medicine, University of Puerto 
      Rico School of Medicine, PO Box 365067, San Juan, PR 00936-5067.
FAU - Mangual, A
AU  - Mangual A
FAU - Velez Garcia, E
AU  - Velez Garcia E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Puerto Rico
TA  - Bol Asoc Med P R
JT  - Boletin de la Asociacion Medica de Puerto Rico
JID - 7505267
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Hypereosinophilic Syndrome/blood/diagnosis/*drug therapy
MH  - Immunoglobulin E/blood
MH  - Interferon alpha-2
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Recombinant Proteins
EDAT- 2001/01/06 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/06 11:00
PHST- 2001/01/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/06 11:00 [entrez]
PST - ppublish
SO  - Bol Asoc Med P R. 2000 Apr-Aug;92(4-8):59-62.